Compare Novo Nordisk A/S (NVO) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Walmart Stores Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Walmart Stores Inc trades at $110.22 (market cap $892.90B). The key difference: Walmart Stores Inc is far larger — about 4× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | WMT | |
|---|---|---|
Market Cap | $220.53B | $892.90B |
Sector | Health | Consumer Staples |
52-Week High | $71.70 | $134.20 |
52-Week Low | $35.29 | $95.67 |
Enterprise Value | $239.49B | $956.35B |
Dividend Yield | 3.63% | 0.88% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Walmart (WMT) trades at $114.24, down 0.62% today, with a neutral technical signal and strong fundamentals including consistent earnings beats and robust cash flow. Revenue reached $681.0B in 2025 (source: company filings, 2025), with net income margin improving to 3.13%. Recent news highlights AI innovation and delivery expansion, while analyst consensus remains bullish with a $142.10 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include competitive pressure from Amazon and margin volatility. Wall Street's strong buy rating (72.72% of analysts) supports upside potential, though investors should monitor execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
